Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohnʼs Disease

(2016) Marla C. Dubinsky et al.   INFLAMMATORY BOWEL DISEASES

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

(2015) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease

(2014) Deirdre Nathalie Dufour et al.   POSTGRADUATE MEDICAL JOURNAL

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

(2013) Alexa B. Kimball et al.   ANNALS OF INTERNAL MEDICINE

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

(2012) C. Leonardi et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

(2012) Irene Cosmatos et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β

(2011) H.H. van der Zee et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions

(2010) P. ETTEHADI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?

(2009) L Matusiak et al.   ACTA DERMATO-VENEREOLOGICA

Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies

(2008) Jean E. Revuz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY